Here's a Quick Look at Merck Stock

By Chris Stiles • Tuesday, September 27 17:04 • Permanent Link

Merck & Company, a pharmaceutical company, marked a -0.4% change today, compared to -0.3% for the S&P 500. Is it a good value at today's price of $85.84? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Merck & Company, belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07
The company's P/B ratio is 5.0
Merck & Company, has a trailing 12 month Price to Earnings (P/E) ratio of 13.1 based on its trailing 12 month price to earnings (Eps) of $6.55 per share
Its forward P/E ratio is 11.6 is, based on its 12 month price to earnings (Eps) is $6.55
MRK has a Price to Earnings Growth ratio of 1.08, which shows the company is fairly valued with respect to its growth potential
Over the last four years, Merck & Company, has averaged free cash flows of $8,462,750,000.0, which on average grew 15.1%
MRK's gross profit margins have averaged 71.3 % over the last four years and during this time they had a growth rate of 2.1 % and a coefficient of variability of 2.7 %.
Merck & Company, has moved 17.5% over the last year compared to -16.0% for the S&P 500 -- a difference of 33.6%
MRK has an average analyst rating of buy and is -14.88% away from its mean target price of $100.85 per share

At Market Interference, we believe in giving retail investors access to timely and accurate data to help inform their investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.